论著

Napsin A、TTF-1及CK7在恶性胸水中对肺腺癌的诊断价值

Diagnostic value of Napsin A, TTF-1 and CK7 for lung adenocarcinoma in malignant pleural effusion cell block

:66-69
 
目的 探讨Napsin A、TTF-1和CK7在恶性胸水细胞蜡块中的表达及对肺腺癌的诊断价值。方法 收集已确诊为恶性胸水且行Napsin A、TTF-1及CK7免疫组化标记,并收集患者的血清和胸水CEA,将患者按组织来源分为肺腺癌组和非肺腺癌组,比较Napsin A、TTF-1、CK7、血清CEA和胸水CEA在两组中的表达和浓度并计算它们的诊断价值。结果 相对于非肺腺癌组,肺腺癌组患者的Napsin A(83.9% vs 16.1%,P<0.001)、TTF-1(93.5% vs 6.5%,P<0.001)和CK7(98.1% vs 1.9%,P<0.001)阳性表达升高。Napsin A诊断肺腺癌的敏感度为83.9%,特异度为93.9%,TTF-1诊断肺腺癌的敏感度为93.5%,特异度为90.9%;CK7诊断肺腺癌的敏感度为98.1%,特异度为42.4%;明显高于传统肿瘤标志物血清CEA(诊断肺腺癌的敏感度为69.7%,特异度为58.5%)和胸水CEA(诊断肺腺癌的敏感度为69.0%,特异度为66.7%)。结论 Napsin A、TTF-1及CK7对于鉴别肺腺癌恶性胸水及其他肿瘤所致的恶性胸水具有较高的诊断价值。
Objective To investigate the expression of Napsin A, TTF-1 and CK7 in paraffin cells block of malignant pleural effusion and their diagnostic value for lung adenocarcinoma. Methods Immunohistochemistry of Napsin A, TTF-1, CK7, serum and pleural fluid CEA were collected from patients with malignant pleural effusion. The patients were divided into lung adenocarcinoma group and non-lung adenocarcinoma groups according to tissue source. The expression of Napsin A, TTF-1, CK7, CEA and the levels of serum and CEA in pleural fluid were compared and their diagnostic value was calculated. Results The positive expression of Napsin A (83.9% vs 16.1%, P<0.001), TTF-1 (93.5% vs 6.5%, P<0.001) and CK7 (98.1% vs 1.9%, P<0.001) in malignant pleural effusion caused by lung adenocarcinoma were higher compared to other tumors. The sensitivity and specificity of Napsin A were 83.9% and 93.9%,the sensitivity and specificity of TTF-1 were 93.5% and 90.9%, and those of CK7 were 98.1% and 42.4%; which were higher than those of serum CEA (69.7% and 58.5%) and pleural fluid CEA (69.0% and 66.7%) respectively. Conclusion Napsin A, TTF-1 and CK7 are of high value in the diagnosis of malignant pleural effusion caused by lung adenocarcinoma from other tumors.
临床诊疗

榄香烯治疗肺癌恶性胸腔积液临床观察

Clinical Observation of Malignant Pleural Effusion of Lung Cancer by Treatment of Elemene

:74-75
 
目的 比较榄香稀和顺铂胸腔灌注治疗肺癌恶性胸腔积液的疗效。方法 肺癌合并恶性胸腔积液患者56例,榄香稀组29例:胸腔内注射榄香烯400 mg+地塞米松10 mg+2%普鲁卡因10 mL;顺铂组27例:顺铂80 mg+地塞米松10 mg。每周1次,治疗4周。同时记录不良反应。结果 56例均可评价疗效,榄香稀组完全缓解11例,部分缓解14例,有效率86.2%。顺铂组完全缓解6例,部分缓解10例,有效率59.3%,差异有统计学意义,榄香稀组生活质量较顺铂组改善。结论 榄香稀治疗恶性胸腔积液疗效好,可提高生活质量,毒副反应小。
出版者信息








《广州医药》公众号